[DOI] [PubMed] [Google Scholar] 9.Rothkopf MM, Bilof ML, Haverstick LP, Nusbaum MJ
GLP-1 Therapies and Risk of Muscle Loss Glucagon-like peptide-1 (GLP-1) medications have increasingly been prescribed to treat cardiometabolic conditions such as obesity, diabetes, and cardiovascular diseasesYeo et al (2024) conducted a nationwide analysis on the usage of GLP-1's in patients without diabetes and observed a 700% (from 21,000 in 2019 to 174,000 in 2023) increase between the years 2019-2023
The plaintiffs proposed this expansion to consolidate claims of potential blood clot-related injuries allegedly linked to these drugs
Advanced packaging solutions are crucial in mitigating these risks
S.WischnewskyM.JaenschA.SteckhanN.StangeR.et al (2018)
Pills may also help people mentally move from seeing GLP-1 drugs as treatment, and instead push the drugs into being part of their routine, perhaps helping to remove stigma around taking them